Metabolic targeted therapy of cancer: Current tracer technologies and future drug design strategies in the old metabolic network

Metabolomics

Volumn 1, Issue 1, 2005, Pages 11-15

  Boros, László G ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Cancer; Drug design; Intermediary metabolism; Stable isotope tracers

Indexed keywords

EID: 22144493335     PISSN: 15733882     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11306-005-1103-7     Document Type: Review

References (31)

1. A. Baron T. Migita D. Tang and M. Loda 2004 Fatty acid synthase: A metabolic oncogene in prostate cancer? J. Cell. Biochem. 91 47-53 10.1002/jcb.10708 1:CAS:528:DC%2BD2cXlvV2gsQ%3D%3D 14689581
2. P.A. Boekhorst B. Lowenberg J. van Kapel K. Nooter and P. Sonneveld 1995 Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia Leukemia 9 1025-1031 7541095
3. J. Boren M. Cascante and S. Marin 2001 Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells J. Biol. Chem. 276 37747-37753 1:CAS:528:DC%2BD3MXotFOrsbY%3D 11489902
4. L.G. Boros J. Puigjaner and M. Cascante 1997 Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation Cancer Res. 57 4242-4248 1:CAS:528:DyaK2sXmsFChu74%3D 9331084
5. L.G. Boros S. Bassilian S. Lim and W.N. Lee 2001a Genistein inhibits non-oxidative ribose synthesis in MIA pancreatic adenocarcinoma cells: A new mechanism of controlling tumor growth Pancreas 22 1-7 10.1097/ 00006676-200101000-00001 1:STN:280:DC%2BD3M7hs1aisQ%3D%3D
6. L.G. Boros K. Lapis and B. Szende 2001b Wheat germ extract decreases glucose uptake and RNA ribose formation but increases fatty acid synthesis in MIA pancreatic adenocarcinoma cells Pancreas 23 141-147 10.1097/00006676-200108000-00004 1:STN:280:DC%2BD38%2FislGqsA%3D%3D
7. L.G. Boros W.N. Lee and V.L. Go 2002a A metabolic hypothesis of cell growth and death in pancreatic cancer Pancreas 24 26-33 10.1097/ 00006676-200201000-00004
8. L.G. Boros M. Cascante and W.N. Lee 2002b Metabolic profiling of cell growth and death in cancer: Applications in drug discovery Drug Discov. Today 7 364-372 10.1016/S1359-6446(02)02179-7 1:CAS:528:DC%2BD38XhvVWhsbg%3D
9. L.G. Boros D.J. Brackett and G.G. Harrigan 2003a Metabolic biomarker and kinase drug target discovery in cancer using stable isotope-based dynamic metabolic profiling (SIDMAP) Curr. Cancer Drug Targets 3 445-453 10.2174/1568009033481769 1:CAS:528:DC%2BD3sXhtVSmurjI
10. L.G. Boros M.P. Steinkamp J.C. Fleming W.N. Lee M. Cascante and E.J. Neufeld 2003b Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA) Blood 102 3556-3561 10.1182/blood-2003-05-1537 1:CAS:528:DC%2BD3sXptVymtro%3D
11. L.G. Boros M. Cascante and W.-N.P. Lee 2003c Stable isotope-based dynamic metabolic profiling in disease and health in G.G. Harrigan and R. Goodacre (Eds) Metabolic profiling: Its role in biomarker discovery and gene function analysis Kluwer Academic Publishers Boston
12. Boros L.G. (2004). Metabolic profile of inflammatory breast cancer: aiding diagnosis and treatment. George Washington University and the IBC Research Foundation co-sponsored "IBC Mini Symposium" hosted by George Washington University: http://www.ibcresearch.org/ibcminisymposium/
13. S.W. Cowan-Jacob V. Guez and G. Fendrich 2004 Imatinib (STI571) resistance in chronic myelogenous leukemia: Molecular basis of the underlying mechanisms and potential strategies for treatment Mini Rev. Med. Chem. 4 285-299 10.2174/1389557043487321 1:CAS:528:DC%2BD2cXisVKhur8%3D 15032675
14. J.E. Dancey and B. Freidlin 2003 Targeting epidermal growth factor receptor - Are we missing the mark? Lancet 362 62-64 10.1016/ S0140-6736(03)13810-X 1:CAS:528:DC%2BD3sXltF2is7w%3D 12853203
15. P. Danzon and A. Towse 2002 The economics of gene therapy and of pharmacogenetics Value Health 5 5-13 10.1046/j.1524-4733.2002.51081.x 11873384
16. E. Eigenbrodt M. Reinacher U. Scheefers-Borchel H. Scheefers and R. Friis 1992 Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells Crit. Rev. Oncog. 3 91-115 1:CAS:528:DyaK2cXhtVens7w%3D 1532331
17. R. Green 2003 Mystery of thiamine-responsive megaloblastic anemia unlocked Blood 102 3464-3465 10.1182/blood-2003-09-3025 1:CAS:528:DC%2BD3sXptVymsLg%3D
18. J.L. Griffin 2004 Metabolic profiles to define the genome: Can we hear the phenotypes? Philos. Trans. R. Soc. Lond. B Biol. Sci. 359 857-871 10.1098/rstb.2003.1411 1:CAS:528:DC%2BD2cXmt1yms70%3D 15306403
19. V. Guillemard and H.U. Saragovi 2004 Novel approaches for targeted cancer therapy Curr. Cancer Drug Targets 4 313-326 10.2174/ 1568009043332989 1:CAS:528:DC%2BD2cXkvFyjsrk%3D 15180497
20. W.K. Hofmann M. Komor D. Hoelzer and O.G. Ottmann 2004 Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia Leuk. Lymphoma 45 655-660 10.1080/ 10428190310001625755 1:CAS:528:DC%2BD3sXpvV2lsbw%3D 15160936
21. W. Hu and J.J. Kavanagh 2003 Anticancer therapy targeting the apoptotic pathway Lancet Oncol. 4 721-729 10.1016/S1470-2045(03)01277-4 1:CAS:528:DC%2BD3sXps1OgsL0%3D 14662428
22. F.P. Kuhajda 2000 Fatty-acid synthase and human cancer: New perspectives on its role in tumor biology Nutrition 16 202-208 10.1016/ S0899-9007(99)00266-X 1:CAS:528:DC%2BD3cXhsFGqu7w%3D 10705076
23. S. Matzku H. Krempel H.P. Weckenmann V. Schirrmacher H. Sinn and H. Stricker 1990 Tumor targeting with antibody-coupled liposomes: Failure to achieve accumulation in xenografts and spontaneous liver metastases. Cancer Immunol. Immunother. 31 285-291 10.1007/BF01740936 1:STN:280:By%2BA38bmtFE%3D 2376046
24. E.R. Nemecek and D.C. Matthews 2003 Use of radiolabeled antibodies in the treatment of childhood acute leukemia Pediatr. Transplant. 3 89-94 10.1034/j.1399-3046.7.s3.14.x
25. H.C. Pitot and J.P. Jost 1967 Control of biochemical expression in morphologically related cells in vivo and in vitro Natl. Cancer Inst. Monogr. 26 145-166 1:STN:280:CCeD1M%2FlsVY%3D 4294465
26. C.M. Rudin J. Holmlund and G.F. Fleming 2001 Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer Clin. Cancer Res. 7 1214-1220 1:CAS:528:DC%2BD3MXktlemu7g%3D 11350886
27. C. Schmidt 2004 Metabolomics takes its place as latest up-and-coming "omic" science J. Natl. Cancer Inst. 96 732-734 15150298
28. A.G. Schwartz L. Pashko and J.M. Whitcomb 1986 Inhibition of tumor development by dehydroepiandrosterone and related steroids Toxicol. Pathol. 14 357-362 1:CAS:528:DyaL2sXitVOruro%3D 3024302
29. N.P. Shah C. Tran F.Y. Lee P. Chen D. Norris and C.L. Sawyers 2004 Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 399-401 10.1126/science.1099480 1:CAS:528:DC%2BD2cXls1egtrY%3D 15256671
30. E.L. Sievers 2000 Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates Cancer Chemother. Pharmacol. 46 S18-S22 1:CAS:528:DC%2BD3cXks1Oksrc%3D 10950142
31. T.A. Smith 1998 FDG uptake, tumor characteristics and response to therapy: A review Nucl. Med. Commun. 19 97-105 1:CAS:528:DyaK1cXhsF2gt7g%3D 9548192